MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/210/0.1/21.03.25 | Market Closed - Börse Stuttgart 03:28:11 2024-06-28 pm EDT | ||
| 0.236 EUR | -1.67% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.236 | -1.67% |
| 24-06-27 | 0.24 | -7.69% |
| 24-06-26 | 0.26 | -13.33% |
| 24-06-25 | 0.3 | +32.16% |
| 24-06-24 | 0.227 | -4.62% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 03:28 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG5D29 |
| ISIN | DE000MG5D291 |
| Date issued | 2024-06-06 |
| Strike | 210 $ |
| Maturity | 2025-03-21 (265 Days) |
| Parity | 10 : 1 |
| Emission price | 0.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.31 € |
|---|---|
| Lowest since issue | 0.199 € |
| Spread | 0.006 € |
| Spread % | 2.52% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
